Author/Editor		Ostanek, Barbara; Marc, Janja
Title		Vloga farmakogenomike v posamezniku prilagojenem zdravljenju osteoporoze
Translated title		The role of pharmacogenomics in personalised treatment of osteoporosis
Type		članek
Source		In: Monografija IV. osteoloških dnevov z mednarodno udeležbo Maribor : Univerzitetni klinični center
Publication year		2013
Volume		str. 263-271
Language		slv
Abstract		Osteoporoza in z njo povezani zlomi postajajo zaradi staranja prebivalstva vse večji svetovni zdravstveni in družbeno-ekonomski problem. Za preprečevanje zlomov imamo na voljo kar nekaj zdravil z različnimi mehanizmi delovanja, v razvoju pa so tudi nova, ki bodo v prihodnosti še razširila obstoječi nabor. Čeprav je zdravljenje dokaj uspešno, se odziv na zdravilo, ki zajema tako učinkovitost zdravljenja kot tudi pojav neželenih učinkov, med posamezniki razlikuje. Pomemben razlog za te razlike lahko predstavljajo karakteristike posameznikovega genoma, ki jih proučuje farmakogenomika (PGx). Osnovni cilj PGx v klinični praksi je z določitvijo genomskih označevalcev pred aplikacijo zdravila predvideti posameznikov odziv na zdravilo in tako prispevati k posamezniku prilagojenem zdravljenju. To bi pomenilo še posebej veliko prednost ravno pri osteoporozi, kjer lahko učinkovitost zdravljenja preverjamo šele po daljšem času, prav tako pa se tudi nekateri neželeni učinki razvijejo šele po dolgotrajnem zdravljenju. V prispevku so predstavljeni pristopi, rezultati, omejitve in možne izboljšave dosedanjih raziskav s področja PGx osteoporoze. Rezultati so preliminarni, nakazujejo pa pomen PGx in smiselnost nadaljnjih študij na ter možnost vključitve PGx v klinično prakso na področju osteoporoze v prihodnosti.The increased incidence of osteoporosis and osteoporotic fractures caused by aging of the world population represents a serious health, social and economic problem. Currently, several antiosteoporotic drugs with different mechanisms of action are available and several new drugs are in development. Osteoporosis treatment is generally quite successful, however interindividual differences in drug response, which includes treatment efficacy as well as adverse drug reactions, can be observed. Common variations in the human genomeare increasingly recognized as the most important cause of variable drugresponse and are studied by pharmacogenomics (PGx). The main goal of PGx in clinical practice is to contribute to personalised treatment. This is accomplished by prediction of individual patient's drug response prior to druga dministration according to the genomic biomarkers determined in a PGx test. PGx could be of great importance especially in osteoporosis, since treatment efficacy can not be determined soon after therapy initiation and because some adverse reactions develop only after years of continous treatment. In this article the approaches, results, limitations and possible improvements in the studies of osteoporosis PGx are described. The preliminary results available are interesting and suggest that osteoporosis PGx should be studied further and could be implemented in the clinical practice in the future.
Keywords		farmakogenetika genetsko testiranje polimorfizem neželeni učinki zdravil odziv na zdravilo